Jpmorgan Chase & CO I Teos Therapeutics, Inc. Transaction History

Jpmorgan Chase & CO

  • $1.27 Trillion
  • Q1 2025

A detailed history of Jpmorgan Chase & CO transactions in I Teos Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 1,982,663 shares of ITOS stock, worth $20.1 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,982,663
Previous 2,068,796 4.16%
Holding current value
$20.1 Million
Previous $15.9 Million 25.5%
% of portfolio
0.0%
Previous 0.0%

Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 12, 2025
SELL
$5.97 - $8.15 $514,214 - $701,983
-86,133 Reduced 4.16%
1,982,663 $11.8 Million
Q4 2024

Feb 12, 2025
BUY
$7.22 - $10.02 $11.6 Million - $16 Million
1,601,477 Added 342.69%
2,068,796 $15.9 Million
Q3 2024

Dec 26, 2024
BUY
$10.09 - $17.97 $54,163 - $96,462
5,368 Added 1.16%
467,319 $4.77 Million
Q3 2024

Nov 08, 2024
BUY
$10.09 - $17.97 $54,163 - $96,462
5,368 Added 1.16%
467,319 $4.77 Million
Q2 2024

Dec 26, 2024
SELL
$10.33 - $18.09 $55,451 - $97,107
-5,368 Reduced 1.15%
461,951 $6.86 Million
Q2 2024

Aug 12, 2024
BUY
$10.33 - $18.09 $4.59 Million - $8.04 Million
444,193 Added 2501.37%
461,951 $6.86 Million
Q1 2024

Dec 26, 2024
SELL
$9.89 - $13.64 $4.45 Million - $6.13 Million
-449,561 Reduced 96.2%
17,758 $242,000
Q1 2024

May 10, 2024
SELL
$9.89 - $13.64 $54,335 - $74,938
-5,494 Reduced 23.63%
17,758 $242,000
Q4 2023

Dec 26, 2024
SELL
$8.57 - $11.06 $3.81 Million - $4.91 Million
-444,067 Reduced 95.02%
23,252 $254,000
Q4 2023

Feb 12, 2024
SELL
$8.57 - $11.06 $3,847 - $4,965
-449 Reduced 1.89%
23,252 $254,000
Q3 2023

Nov 14, 2023
BUY
$10.95 - $14.6 $35,620 - $47,493
3,253 Added 15.91%
23,701 $259,000
Q2 2023

Aug 11, 2023
SELL
$12.93 - $18.05 $6.54 Million - $9.13 Million
-505,709 Reduced 96.11%
20,448 $270,000
Q1 2023

May 18, 2023
BUY
$13.02 - $22.62 $391,198 - $679,640
30,046 Added 6.06%
526,157 $7.16 Million
Q1 2023

May 11, 2023
SELL
$13.02 - $22.62 $1.14 Million - $1.99 Million
-87,847 Reduced 15.04%
496,111 $6.75 Million
Q4 2022

Feb 13, 2023
BUY
$17.77 - $21.6 $729,511 - $886,744
41,053 Added 7.56%
583,958 $11.4 Million
Q3 2022

Nov 14, 2022
SELL
$18.6 - $27.25 $304,928 - $446,736
-16,394 Reduced 2.93%
542,905 $10.3 Million
Q2 2022

Aug 11, 2022
BUY
$16.57 - $35.1 $5.51 Million - $11.7 Million
332,625 Added 146.74%
559,299 $11.5 Million
Q1 2022

May 11, 2022
BUY
$31.92 - $47.45 $5.36 Million - $7.97 Million
167,992 Added 286.28%
226,674 $7.3 Million
Q4 2021

Feb 10, 2022
BUY
$26.23 - $47.86 $1.16 Million - $2.11 Million
44,131 Added 303.28%
58,682 $2.73 Million
Q3 2021

Nov 12, 2021
BUY
$23.91 - $29.58 $347,914 - $430,418
14,551 New
14,551 $393,000

Others Institutions Holding ITOS

# of Institutions
143
Shares Held
37.7M
Call Options Held
733K
Put Options Held
611K
View Full List

About iTeos Therapeutics, Inc.

ITOS Quotes by TradingView
  • Ticker ITOS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 35,575,300
  • Market Cap $361M
  • Description
  • Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or ...
More about ITOS
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email